What top creators are saying about Iovance Biotherapeutics, Inc.(IOVA)

Mentioned among stocks with large year-to-date gains, with no specific return or investment thesis provided.

Further upside was possible after a strong rally, but the host also highlighted taking some profits and noted the stock had not formed a higher low since around $3.69.

The speaker said he did not know the company well and offered no assessment.

The speaker said he did not know the company well enough to comment.

The speaker expected continued gains but later called the stock overextended and potentially a good short, reflecting conflicting short-term trading observations.

The speaker cited raised guidance, a rally from about $8 to $13, and perceived institutional underownership as reasons the stock might rise further, while warning it was extended and could retrace.

The stock's sharp rally and possible overextension raised pullback risk, while low institutional ownership and a guidance increase could support further demand. The host did not settle on a long or short view.

The stock was said to be up nearly 300%, but no explanation, position, or directional outlook was provided.

Noted as being up nearly 300%, but no investment thesis or recommendation was given.